Jefferies Maintains Buy Rating for CVS Health (CVS) with Price Target of $80
Written by Emily J. Thompson, Senior Investment Analyst
Source: Yahoo Finance
Updated: Aug 31 20250mins
CVS Health Corporation Overview
Stock Ratings and Price Targets: CVS Health Corporation (NYSE: CVS) is currently viewed as one of the most undervalued low volatility stocks. Jefferies analyst Brian Tanquilut has reiterated a Buy rating with a price target of $80.00, while UBS has also upgraded the stock to Buy with a target of $79.00.
Fiscal Q2 2025 Financial Performance: For the fiscal Q2 2025, CVS reported total revenues of $98.9 billion, reflecting an 8.4% increase year-over-year. The GAAP diluted earnings per share (EPS) was $0.80, and the adjusted EPS stood at $1.81. The company generated $6.5 billion in cash flow from operations year-to-date.
Market Insights
Stock Price Potential: The median price target for CVS stock is $71.93, indicating a potential upside of 11.91% from its current trading levels.
Company Segments: CVS operates in four main segments: healthcare benefits, health services, pharmacy & consumer wellness, and corporate/other. It is not only a leading pharmacy chain but also one of the largest health insurers in the U.S. through its Aetna subsidiary.
Investment Considerations
Comparison with AI Stocks: While CVS presents a solid investment opportunity, there is a belief that certain AI stocks may offer greater upside potential with less downside risk. The article suggests exploring undervalued AI stocks that could benefit from current economic trends, including tariffs and onshoring.
Additional Resources: The article references further reading on stocks expected to double in three years and hidden AI stocks worth buying.
CVS.N
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on CVS
Wall Street analysts forecast CVS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CVS is 90.53 USD with a low forecast of 75.00 USD and a high forecast of 102.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
16 Analyst Rating
15 Buy
1 Hold
0 Sell
Strong Buy
Current: 80.830
Low
75.00
Averages
90.53
High
102.00
Current: 80.830
Low
75.00
Averages
90.53
High
102.00
Bernstein
Bernstein
Market Perform
maintain
$86 -> $87
2025-12-12
New
Reason
Bernstein
Bernstein
Price Target
$86 -> $87
2025-12-12
New
maintain
Market Perform
Reason
Bernstein raised the firm's price target on CVS Health to $87 from $86 and keeps a Market Perform rating on the shares following overall a very positive Investor Day event. The firm cites increased confidence in quality and depth of management teams, and reinforcement of the quality and market leadership of leading companies.
Baird
Outperform
maintain
$82 -> $92
2025-12-10
New
Reason
Baird
Price Target
$82 -> $92
2025-12-10
New
maintain
Outperform
Reason
Baird raised the firm's price target on CVS Health to $92 from $82 and keeps an Outperform rating on the shares. The firm updated its model and believes its bull thesis remains intact.
Mizuho
Ann Hynes
Outperform
maintain
$88 -> $95
2025-12-10
New
Reason
Mizuho
Ann Hynes
Price Target
$88 -> $95
2025-12-10
New
maintain
Outperform
Reason
Mizuho analyst Ann Hynes raised the firm's price target on CVS Health to $95 from $88 and keeps an Outperform rating on the shares, telling investors that the company provided "several positive updates" at its bi-annual investor day, including updated 2025 guidance, detailed 2026 guidance, and a raised long-term earnings growth outlook. CVS is the top pick in the analyst's coverage universe, the analyst noted.
Truist
Buy
maintain
$95 -> $98
2025-12-10
New
Reason
Truist
Price Target
$95 -> $98
2025-12-10
New
maintain
Buy
Reason
Truist raised the firm's price target on CVS Health to $98 from $95 and keeps a Buy rating on the shares. The firm remains bullish on CVS post an upbeat Investor Day highlighting the company's differentiated collection of assets, strong positioning and opportunities across segments, alongside the announced launch of a centralized engagement platform in FY26, the analyst tells investors in a research note. Brisk cash flow and ongoing balance sheet improvement underpins continued core growth investment, the firm added.
See All Ratings
About CVS
CVS Health Corporation is a health solutions company. The Company's segments include Health Care Benefits, Health Services, Pharmacy & Consumer Wellness and Corporate/Other. Health Care Benefits segment offers a broad range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, PDPs and Medicaid health care management services. Health Services segment provides a full range of pharmacy benefit management (PBM) solutions through its CVS Caremark operations and delivers health care services in its medical clinics, virtually, and in the home. Pharmacy & Consumer Wellness segment dispenses prescriptions in its CVS Pharmacy retail locations and through its infusion operations, provides ancillary pharmacy services including pharmacy patient care programs, diagnostic testing and vaccination administration, and sells a wide assortment of health and wellness products and general merchandise.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
What factors contributed to CVS Health's improved long-term growth projections?
How does CVS's consumer engagement platform enhance its business integration?
Will CVS Health achieve its mid-teens adjusted EPS CAGR through 2028?
How might CVS's 2026 revenue forecast impact its stock performance?